What one share of Sionna Therapeutics holds
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to people with CF.
Sionna Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.17 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.70 |
| Cash and investments | $1.40 |
| Book value | $5.88 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$15.99 | $0.01 | −$13.69 | — | −$34.66 |
| 2025 | — | −$1.88 | $0.01 | −$1.67 | — | $6.86 |
Common questions about Sionna Therapeutics
How much does one share of Sionna Therapeutics earn?
Over the last 12 months, Sionna Therapeutics lost $2.17 for each share.
Does Sionna Therapeutics pay a dividend?
Sionna Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Sionna Therapeutics’s book value per share?
Sionna Therapeutics’s book value is $5.88 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Sionna Therapeutics have?
Each share of Sionna Therapeutics has $1.40 of cash and investments, as of June 30, 2026.
What is Sionna Therapeutics’s free cash flow per share?
−$1.70 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.